Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia

Chest

Volumn 141, Issue 4, 2012, Pages 974-982

  Nowak, Albina ^a,b   Breidthardt, Tobias ^a   Christ Crain, Mirjam ^a   Bingisser, Roland ^a   Meune, Christophe ^a   Tanglay, Yunus ^a   Heinisch, Corinna ^a   Reiter, Miriam ^a   Drexler, Beatrice ^a   Arenja, Nisha ^a   Twerenbold, Raphael ^a   Stolz, Daiana ^a   Tamm, Michael ^a   Müller, Beat ^c   Müller, Christian ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; PROATRIAL NATRIURETIC FACTOR; UNCLASSIFIED DRUG; UREA;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CLINICAL EVALUATION; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA SEVERITY INDEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; UREA BLOOD LEVEL;

EID: 84859516567     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0824     Document Type: Article

References (27)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310. (Pubitemid 32641789)
2. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. (Pubitemid 27044625)
3. Aronsky D, Haug PJ. Assessing the quality of clinical data in a computer-based record for calculating the pneumonia severity index. J Am Med Inform Assoc. 2000;7(1):55-65. (Pubitemid 30041731)
4. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med. 2005;258(4):391-393. (Pubitemid 41368692)
5. Christ-Crain M, Breidthardt T, Stolz D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med. 2008;264(2):166-176. (Pubitemid 351962572)
6. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-849. (Pubitemid 43799232)
7. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50(1):234-236. (Pubitemid 38125732)
8. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-2076.
9. Potocki M, Breidthardt T, Reichlin T, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med. 2010;267(1):119-129.
10. Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T; CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax. 2010;65(3):208-214.
11. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84-93. (Pubitemid 43955248)
12. Potocki M, Breidthardt T, Reichlin T, et al. Midregional proadrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study. Crit Care. 2009;13(4):R122.
13. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382. (Pubitemid 36560938)
14. Ala-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004;50(9):1576-1588. (Pubitemid 39121226)
15. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem. 2004;41(Pt 6):459-463. (Pubitemid 39574001)
16. Schuetz P, Wolbers M, Christ-Crain M, et al; ProHOSP Study Group. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14(3):R106.
17. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and infl ammatory biomarkers to predict short- and long-term survival in community-acquired pneu monia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010;182(11):1426-1434.
18. Jeong KY, Kim K, Kim TY, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J. 2011;28(2):122-127.
19. Naito T, Suda T, Yasuda K, et al. A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. J Am Geriatr Soc. 2006;54(8):1212-1219. (Pubitemid 44166525)
20. Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005;9(suppl 4):S13-S19. (Pubitemid 41498527)
21. Jianhui L, Rosenblatt-Velin N, Loukili N, et al. Endotoxin impairs cardiac hemodynamics by affecting loading conditions but not by reducing cardiac inotropism. Am J Physiol Heart Circ Physiol. 2010;299(2):H492-H501.
22. McCullough PA, Duc P, Omland T, et al Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571-579. (Pubitemid 36278374)
23. Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53(19):1783-1790.
24. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49-57.
25. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O. Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol. 2010;99(7):445-452.
26. deFilippi CR, Christenson RH. B-type natriuretic peptide (BNP)/NT-proBNP and renal function: is the controversy over? Clin Chem. 2009;55(7):1271-1273.
27. Pereira M, Azevedo A, Severo M, Barros H. Long-term stability of endogenous B-type natriuretic peptide after storage at -20 degrees C or -80 degrees C. Clin Chem Lab Med. 2008;46(8):1171-1174